Difference between revisions of "Interferon alfa-2b (Intron-A)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.spfiles.com/piintrona.pdf Interferon alfa-2b (Intron-A) package insert]</ref><ref>[http://hemonc.org/docs/...")
 
Line 1: Line 1:
 
==General information==
 
==General information==
Class/mechanism: <ref name="insert">[http://www.spfiles.com/piintrona.pdf Interferon alfa-2b (Intron-A) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/Interferonalfa-2b.pdf Interferon alfa-2b (Intron-A) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways.  Mechanism not fully understood.<ref name="insert">[http://www.spfiles.com/piintrona.pdf Interferon alfa-2b (Intron-A) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/Interferonalfa-2b.pdf Interferon alfa-2b (Intron-A) package insert (locally hosted backup)]</ref><ref>[http://www.introna.com Intron-A manufacturer's website]</ref>
<br>Route: TBD
+
<br>Route: SC, IM, IV, intralesional
<br>Extravasation: TBD
+
<br>Extravasation: no information
  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>.  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>.  
Line 8: Line 8:
 
==Patient drug information==
 
==Patient drug information==
 
*[http://chemocare.com/bio/intron_a.asp Interferon alfa-2b (Intron-A) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/intron_a.asp Interferon alfa-2b (Intron-A) patient drug information (Chemocare)]</ref>
 
*[http://chemocare.com/bio/intron_a.asp Interferon alfa-2b (Intron-A) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/intron_a.asp Interferon alfa-2b (Intron-A) patient drug information (Chemocare)]</ref>
*[http://www.uptodate.com/contents/Interferonalfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/Interferonalfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]</ref>
+
*[http://www.uptodate.com/contents/interferon-alfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/interferon-alfa-2b-patient-drug-information Interferon alfa-2b (Intron-A) patient drug information (UpToDate)]</ref>
  
 
==References==
 
==References==
 
<references/>
 
<references/>

Revision as of 16:55, 22 February 2012

General information

Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways. Mechanism not fully understood.[1][2][3]
Route: SC, IM, IV, intralesional
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].

Patient drug information

References